1 / 57

Breast Conference 7/13/2011

Breast Conference 7/13/2011. RC 2896849. 51 AAF presenting with abnormal mammogram. RC 2896849. Menarche: 12 y G1P1 (40y), breastfeeding: none OCP: none HRT: none Premenopausal Hx breast bx: none Hx breast Ca: none Fhx: aunt – breast ca,

vila
Download Presentation

Breast Conference 7/13/2011

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Breast Conference 7/13/2011

  2. RC 2896849 51 AAF presenting with abnormal mammogram

  3. RC 2896849 • Menarche: 12 y • G1P1 (40y), breastfeeding: none • OCP: none • HRT: none • Premenopausal • Hx breast bx: none • Hx breast Ca: none • Fhx: aunt – breast ca, father – prostate ca, grandmother – colon ca • Shx: caffeine(-), soy(-), tobacco(-), ETOH(-) • Bra: 40DD

  4. RC 2896849 • PMH: none • PSH: none • Meds: Lorazepam • NKDA

  5. RC 2896849 • PE: • Right breast: no masses, no skin changes • Left breast: hard mass 12:00, diameter 2cm • Left axillary lymphadenopathy

  6. RC 2896849 • Radiology: • Screening mammogram: lt. breast asymmetry, enlarged LN • Diagnostic mammogram: lt. breast nodular densities, enlarged LN • US: lt. breast 0.9*0.8*0.8cm lesion, 1.9*1.1*1.5cm axillary LN • MRI: lt. breast 11-12:00, 1.1*2.2*1.1cm lesion, axillary adenopathy • PET/CT: lt. breast and axillary hypermetabolic activity

  7. RC

  8. RC

  9. RC

  10. RC

  11. RC

  12. RC

  13. RC 2896849 • Pathology: • Breast lesion: Invasive Ductal Carcinoma, grade 3 ER(-) PR(-), HER2(+1) • Axillary lesion: metastatic Ductal Carcinoma

  14. RC 2896849 • Clinical stage IIb: T2N1M0

  15. RC 2896849

  16. RC 2896849

  17. RC 2896849

  18. RC 2896849

  19. RC 2896849 • Surgery – lumpectomy + ALND • Medical oncology – • Radiation oncology – • Plastic surgery – • Genetics – • Psychosocial –

  20. First mention in publication – Oct 2005 • Mostly Basal-like carcinoma, but also Claudin low and Normal-like • Basal-like: triple negative + CK5 or EGFR

  21. 15% of invasive Breast Carcinoma • High grade, larger • More likely to be node negative • Young, African American and Hispanic women • Earlier menarche, higher BMI, higher parity, lower duration of breast feeding • Adverse prognosis • Distant relapse is uncommon after 3-5 years from diagnosis

  22. Breast tumors are heterogeneous • Cells of origin of different tumors correspond with normal mammary cells in the differentiation path • Triple Negative tumors possess phenotypic characteristics of mammary stem cells • Basal-like carcinoma probably arises from luminal progenitor cells, which express both luminal and basal markers

  23. Visvader, 2009

  24. >75% of tumors in BRCA1 pts are Triple Negative, Basal-like or both • Tumors in women with BRCA1 mutation have similarities in morphology and gene expression with Basal-like cancer

  25. Rapid growth • Over-represented in woman with interval cancers • More likely to recur locally than ER+ cancer

  26. Treatment: • Patients do not benefit from endocrine therapy • No specific chemotherapy • Use of targeted agents is investigated – bevacizumab, cetuximab , PARP inhibitors

  27. Multidisciplinary Breast Cancer Conference Laleh Amiri 7-13-2011

  28. Case CB 48 y/o f. 1/18/2011 screening mgm : calcifications in both breasts + a mass in the L breast. 4/5/2011 diagnostic mgm & US with comparison to old films: 2 new clusters of calcifications in the LUI Q @3:00 & 10:00 + cyst. 5/6/11 stereotactic bxs :sclerosing adenosis and calcifications + focal atypical lobular hyperplasia in 3:00 bx site. 6/21/11 excisional biopsy: focal ALH.

  29. All: Gluten Med: MVI PMH: h/o depression. vitamin D deficiency.  PSH: Cholecystectomy, rhinoplasty, hemorrhoidectomy GynHx:G1P1, first birth @38, 1st menstrual period:13, OCP <1y, LMP 6/23/11.  FHx: PGM BC 60s. 1st cousin with mBC 40s. SoHx: Born in Ireland. Married,8 y/o son. lives in Rockville. works for FDA. Drinks rarely. Never tob. ROS: negative Ph/EX: negative

  30. Questions Does she really have ALH? Was excisional biopsy necessary? What is her risk for developing IDC? Management of ALH? Role of MRI for screening?

  31. Questions Does she really have ALH? Was excisional biopsy necessary? What is her risk for developing IDC? Management of ALH? Role of MRI for screening?

  32. Breast J. 2007 Jan-Feb;13(1):55-61.

  33. Breast J. 2007 Jan-Feb;13(1):55-61.

  34. Questions Does she really have ALH? Was excisional biopsy necessary? What is her risk for developing IDC? Management of ALH? Role of MRI for screening?

  35. Questions Does she really have ALH? Was excisional biopsy necessary? What is her risk for developing IDC? Management of ALH in premenopausal woman? Role of MRI for screening?

  36. NSABP P1 Fisher J Natl Cancer Inst, 2005

  37. NSABP P1 Fisher J Natl Cancer Inst, 2005

  38. Fisher J Natl Cancer Inst, 2005 NSABP P1 Benefits and risks associated with tamoxifen use for breast cancer risk Reduction.

  39. NSABP P1 Fisher J Natl Cancer Inst, 2005

  40. Questions Does she really have ALH? Was excisional biopsy necessary? What is her risk for developing IDC? Management of ALH? Role of MRI for screening?

  41. American Cancer Society Guidelines CA Cancer J Clin 2007;57:75–89

  42. KB

  43. KB

  44. KB

More Related